Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis

被引：62

作者：

Chamian, Francesca ^{[1
]}

Lin, Shao-Lee ^{[1
]}

Lee, Edmund ^{[1
]}

Kikuchi, Toyoko ^{[1
]}

Gilleaudeau, Patricia ^{[1
]}

Sullivan-Whalen, Mary ^{[1
]}

Cardinale, Irma ^{[1
]}

Khatcherian, Artemis ^{[1
]}

Novitskaya, Inna ^{[1
]}

Wittkowski, Knut M. ^{[1
]}

Krueger, James G. ^{[1
]}

Lowes, Michelle A. ^{[1
]}

机构：

[1] Rockefeller Univ, Invest Dermatol Lab, New York, NY 10021 USA

来源：

JOURNAL OF TRANSLATIONAL MEDICINE | 2007年 / 5卷 / 1期

关键词：

D O I：

10.1186/1479-5876-5-27

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background: Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease. Methods: Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis. Results: In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7(-) CD45RA(-)) ( mean 63% reduction) for both CD4(+) and CD8(+) Tem, while central memory T cells (Tcm) ( CCR7(+) CD45RA(-)) were less affected, and nave T cells (CCR7(+) CD45RA(+)) were relatively spared. Circulating CD8(+) effector T cells and Type 1 T cells ( IFN-gamma- producing) were also significantly reduced. Conclusion: Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells ( Tcm) in psoriasis.

引用

页数：7

共 23 条

[1] The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations:: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients [J].

Austin, LM ;

Ozawa, M ;

Kikuchi, T ;

Walters, IB ;

Krueger, JG .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (05) :752-759

[2]

BACCHMANN MF, 2003, J IMMUNOL, V190, P1383

[3] Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris [J].

Chamian, F ;

Lowes, MA ;

Lin, SL ;

Lee, E ;

Kikuchi, T ;

Gilleaudeau, P ;

Sullivan-Whalen, M ;

Cardinale, I ;

Khatcherian, A ;

Novitskaya, I ;

Wittkowski, KM ;

Krueger, JG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (06) :2075-2080

[4] PROLONGATION OF ALLOGRAFT AND XENOGRAFT SURVIVAL IN MICE BY ANTI-CD2 MONOCLONAL-ANTIBODIES [J].

CHAVIN, KD ;

LAU, HT ;

BROMBERG, JS .

TRANSPLANTATION, 1992, 54 (02) :286-291

[5]

Crawford K, 1999, J IMMUNOL, V163, P5920

[6] Alefacept, an immunomodulatory recombinant FA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2+ cells [J].

da Silva, AJ ;

Brickelmaier, M ;

Majeau, GR ;

Li, ZF ;

Su, LH ;

Hsu, YM ;

Hochman, PS .

JOURNAL OF IMMUNOLOGY, 2002, 168 (09) :4462-4471

[7]

Di Pucchio T, 2003, EUR J IMMUNOL, V33, P358

[8]

Dumont C, 1998, J IMMUNOL, V160, P3797

[9] ROLE OF LYMPHOCYTE ADHESION RECEPTORS IN TRANSIENT INTERACTIONS AND CELL LOCOMOTION [J].

DUSTIN, ML ;

SPRINGER, TA .

ANNUAL REVIEW OF IMMUNOLOGY, 1991, 9 :27-66

[10] Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes [J].

Ellis, CN ;

Krueger, GG .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (04) :248-255

← 1 2 3 →